4-aminopyridine has been researched along with Muscle Weakness in 7 studies
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome." | 2.76 | Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases. ( Bertorini, TE; Igarashi, M; Li, YD; Rashed, H; Tolley, EA; Zeno, M, 2011) |
| "Fast channel congenital myasthenic syndromes are rare, but frequently result in severe weakness." | 1.38 | Clinical features in a series of fast channel congenital myasthenia syndrome. ( Bailey, S; Beeson, D; Carr, A; Jayawant, S; Lashley, D; McConville, J; Palace, J; Robb, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thakkar, N | 1 |
| Guptill, JT | 1 |
| Aleš, K | 1 |
| Jacobus, D | 1 |
| Jacobus, L | 1 |
| Peloquin, C | 1 |
| Cohen-Wolkowiez, M | 1 |
| Gonzalez, D | 1 |
| Oh, SJ | 1 |
| Morsch, M | 1 |
| Reddel, SW | 1 |
| Ghazanfari, N | 1 |
| Toyka, KV | 1 |
| Phillips, WD | 1 |
| Bertorini, TE | 1 |
| Rashed, H | 1 |
| Zeno, M | 1 |
| Tolley, EA | 1 |
| Igarashi, M | 1 |
| Li, YD | 1 |
| Palace, J | 1 |
| Lashley, D | 1 |
| Bailey, S | 1 |
| Jayawant, S | 1 |
| Carr, A | 1 |
| McConville, J | 1 |
| Robb, S | 1 |
| Beeson, D | 1 |
| Morbiato, L | 1 |
| Carli, L | 1 |
| Johnson, EA | 1 |
| Montecucco, C | 1 |
| Molgó, J | 1 |
| Rossetto, O | 1 |
| Aisen, ML | 1 |
| Sevilla, D | 1 |
| Edelstein, L | 1 |
| Blass, J | 1 |
3 trials available for 4-aminopyridine and Muscle Weakness
| Article | Year |
|---|---|
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Arylamine N-Acetyltransferase; Femal | 2017 |
Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cross-Over Studies; Double-Blind Met | 2011 |
A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
Topics: 4-Aminopyridine; Administration, Oral; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cross-Ove | 1996 |
4 other studies available for 4-aminopyridine and Muscle Weakness
| Article | Year |
|---|---|
3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Muscle Weakness; Potassiu | 2018 |
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Cholinesterase Inhibitors; Evoked Potential | 2013 |
Clinical features in a series of fast channel congenital myasthenia syndrome.
Topics: 4-Aminopyridine; Adult; Amifampridine; Child; Child, Preschool; Humans; Infant; Middle Aged; Muscle | 2012 |
Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Botulinum Toxins, Type A; Drug Resistance | 2007 |